Swiss Re (ETR:SR9) stock price target increased to 96.00EUR, issued a report today by Kepler Cheuvreux
- Updated: November 29, 2016
Having a price of 92.95EUR, Swiss Re (ETR:SR9) traded 0.00% even on the day. With the last close up 0.00% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. SR9 has recorded a 50-day average of 0.00EUR and a two hundred day average of 0.00EUR. Volume of trade held steady, with 0 shares of SR9 changing hands on par with the typical 0
In a report released on Tuesday November 29, 2016 Kepler Cheuvreux increased the stock price target of Swiss Re (ETR:SR9) to 96.00EUR indicating a possible upside of 0.03%.
On 11/23/2016, Macquarie Research released a statement on Swiss Re (ETR:SR9) upped the target price from 0.00EUR to 100.00EUR that suggested an upside of 0.07%.
With a total market value of 0 EUR, Swiss Re has 52 week low of 0.00EUR and a 52 week high of 0.00EUR .
About Swiss Re (ETR:SR9)
Swiss Re AG is a wholesale provider of reinsurance, insurance and other insurance-based forms of risk transfer. The Company's clients include insurance companies, mid- to large-sized corporations and public sector clients. Its segments include Property&Casualty Reinsurance, Life&Health Reinsurance, Corporate Solutions and Admin Re. Its Reinsurance Unit provides premiums and fee income through Property&Casualty and Life&Health segments. The Corporate Solutions segment is engaged in serving mid-sized and large corporations, with product offerings ranging from traditional property and casualty insurance to customized solutions. The Admin Re segment provides risk and capital management solutions by which the Company acquires closed books of in-force life and health insurance business, entire lines of business, or the entire capital stock of life insurance companies. The Company's open and closed life insurance books, including Admin Re, are managed under a unit called Life Capital.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.